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Background: It is well known that molecular-targeted drugs, of which sorafenib (Nexavar®) is one, differ from previous
anticancer drugs and cause various unusual adverse drug reactions. Treatment with sorafenib causes adverse drug
reactions such as hand-foot skin reactions, hypertension, and diarrhea. Physicians spend a lot of time monitoring
adverse drug reactions to sorafenib in outpatients. As such, at Okayama University Hospital, pharmacists and nurses
have organized a medical supportive team to help physicians in this regard. However, the effectiveness of interventions
for sorafenib-treated outpatients by this medical supportive team remains unclear. The purpose of this study was thus
to clarify the effectiveness of interventions for sorafenib-treated outpatients by this medical supportive team.
Methods: We retrospectively studied 70 outpatients treated with sorafenib between May 2009 and December 2012 at
Okayama University Hospital. These outpatients were classified into two groups, an intervention group (31 outpatients)
and a non-intervention group (39 outpatients). We compared the duration of sorafenib treatment between these groups.
Results: The duration of treatment with sorafenib was significantly longer in the intervention group than in the
non-intervention group. No outpatients in the intervention group discontinued sorafenib due to adverse drug
reactions such as hand-foot skin reactions or diarrhea.
Conclusion: The duration of sorafenib treatment was significantly longer in the intervention group than in the
non-intervention group. Our findings suggest that interventions by the medical supportive team consisting of
health care professionals were effective in preventing the discontinuation of sorafenib.
Keywords: Sorafenib, Hepatocellular carcinoma, Renal cell carcinoma, Adverse drug reactions, Hand-foot skin reactions,
Medical supportive team, OutpatientBackground
Sorafenib (Nexavar®) is one of the oral molecular-targeted
drugs used as systemic treatment in patients with unresect-
able hepatocellular carcinoma and advanced renal cell car-
cinoma [1-3]. It inhibits the activity of serine/threonine
kinases of RAF, protein kinases of MEK and ERK, and blocks
vascular endothelial growth factor receptors (VEGFR),
platelet-derived growth factor receptors (PDGFR), the
cytokine receptor c-KIT, and the receptor tyrosine
kinase Flt-3 to inhibit tumor angiogenesis and tumor
cell growth [4-6].* Correspondence: kitamu-y@cc.okayama-u.ac.jp
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unless otherwise stated.Molecular-targeted drugs were initially expected to cause
less severe adverse drug reactions than previous anticancer
drugs. However, they have been shown to cause various
unusual adverse drug reactions. Sorafenib also causes many
adverse drug reactions, such as hand-foot skin reactions,
diarrhea, and hypertension [2,7,8]. Therefore, the dose of
sorafenib has been decreased or sorafenib treatment
has been discontinued [9,10]. In some hospitals, outpatients
undergo interventions by a medical supportive team to pre-
vent adverse drug reactions. We organized a medical
supportive team consisting of pharmacists and nurse at
Okayama University Hospital (Figure 1). Physicians do not
have enough time in their limited consultations with outpa-
tients to establish the adverse drug reactions of sorafenib.
Pharmacists and nurse thus met with outpatients duringl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Participation of the medical supportive team for those administered sorafenib in Okayama University Hospital.
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gestions on monitoring sheets regarding the problems
encountered by patients, such as the grade of adverse
drug reactions and afflictions. Furthermore, we also pro-
vided outpatients with some advice related to their prob-
lems, including adverse drug reactions or difficulties in
daily life. If hand-foot skin reactions occurred, the team
took pictures of the patient’s hand, foot, and skin, and
posted them in an electronic medical record system. Thus,
the medical supportive team supported physicians regard-
ing the problems encountered by patients. Active partici-
pation of the medical supportive teams has been reported
in the management of patients [11,12]. However, the ef-
fectiveness of interventions for patients by medical sup-
portive teams has not been demonstrated. In our hospital,
our medical supportive team initially intervented in cases
with sorafenib treatment. In the present study, we exam-
ined whether a prolonged duration of sorafenib treatment
in outpatients could be identified in association with inter-
ventions by the medical supportive team in our hospital.
Methods
Patients
We retrospectively screened outpatients with hepatocel-
lular carcinoma and advanced renal cell carcinoma (70
patients) who had been treated with sorafenib between
May 2009 and December 2012 at Okayama University
Hospital. Outpatients were categorized according to age,
gender, an Eastern Cooperative Oncology Group (ECOG)
performance status of 0–2, previous therapy, metastatic
site, and Child-Pugh classification for hepatocellular car-
cinoma patients. This study was approved by the Okayama
University Graduate School of Medicine, Dentistry, and
Pharmaceutical Sciences Ethics Committee (No. 650).
The roles of the medical supportive team for sorafenib
treatment
Our team is composed of two pharmacists (one Japanese
Society of Pharmaceutical Health Care and Sciences-
certified oncology pharmacist and one board certified
pharmacist in oncology pharmacy) and one nurse (certifiednurse in cancer chemotherapy nursing). One pharma-
cist and the nurse always intervene per patient, and the
frequency of intervention is once every month. We check
the medical situation, dose, and adverse events before a
doctor’s examination. The main work of our team is to
consider the advisability of administrating particular anti-
cancer agents and other prescription drugs based on pa-
tient consultation, and to make recommendations to the
physicians in charge.Outcome evaluation
We categorized outpatients into two groups based on
whether or not they had been undergone on intervention
by the medical supportive team in terms of the duration of
sorafenib treatment. The intervention by the medical sup-
portive team was decided according to the physician’s
requirements. Patients were excluded from this study
based on the guidelines for the appropriate use of soraf-
enib as follws: those with progressive disease, grade 2
hand-foot skin reactions more than 4 times, or grade 3
hand-foot skin reactions more than 3 times. When other
non-hematotoxicities occurred, the sorafenib treatment
had to be interrupted for more than 30 days. In addition,
sorafenib treatment was also discontinued when the pri-
mary care physician considered continuation of the treat-
ment to be unnecessary or a reduction in the sorafenib
dose by 2 levels or more to be necessary. Adverse drug
reactions were assessed according to the National Cancer
Institute Common Terminology Criteria for Adverse Events
(NCI-CTCAE), version 4.0.Statistical analysis
Categorical variables were compared by Fisher’s exact test,
and the means of the two groups were analyzed by inde-
pendent t-test. The duration of treatment was analyzed
using Kaplan-Meier survival curves with log-rank survival
comparisons. Significance was set at P <0.05. Statistical
analysis was performed with the Statistical Package for
the Social Sciences software, version 21 (IBM SPSS, Inc.
Chicago, IL, USA).
Table 1 Patient characteristics
Intervention
group n = 31 (%)
Non‐intervention
group n = 39 (%)
P-value












































Table 1 Patient characteristics (Continued)





Abbreviations: ECOG PS: Eastern Cooperative Oncology Group performance
status; HCC: hepatocellular carcinoma; RCC: renal cell carcinoma; TACE:
transarterial chemoembolization; HAIC: hepatic arterial infusion chemotherapy;
RFA: radiofrequency ablation; TAI: transcatheter arterial infusion.
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Patient characteristics
In this study, 72 outpatients were screened. Two patients
were excluded from the analysis; one had not undergone
an intervention by the medical supportive team and the
other was only administered sorafenib for one day be-
cause of adverse drug reactions. Therefore, 70 outpatients
were classified into two groups: an intervention group and
a non-intervention group, according to interventions by
the medical supportive team. No significant differences
were observed in the baseline characteristics between
the two groups, except for diagnosis (Table 1).
Duration of the sorafenib treatment
The duration of the sorafenib treatment was signifi-
cantly longer in the intervention group than in the non-
intervention group (P = 0.008) (Figure 2). In the non-
intervention group, 7 patients stopped using sorafenib
due to adverse drug reactions that were potentially tol-
erable. Table 2 shows the reasons for the discontinuation of
sorafenib in the non-intervention group. The dosage of so-
rafenib was not decreased from 800 mg/day in three
cases. However, sorafenib treatment was interrupted inFigure 2 Effect of interventions by the medical supportive
team on the duration of sorafenib treatment in outpatients.
Table 2 Discontinuation of sorafenib in the non-intervention group (n = 7)
Adverse drug reactions (Grade) Daily dose (mg) Diagnosis Previous therapy
Hand-foot skin reaction (3) 800 hepatocellular carcinoma TACE, RFA, Operation
Hand-foot skin reaction (3) 800 renal cell carcinoma Interleukin
Hand-foot skin reaction (2) 800 renal cell carcinoma Interferon, Sunitiniba
Hand-foot skin reaction (3) 200 hepatocellular carcinoma TACE, RFA
Anorexia (2) 400 renal cell carcinoma None
Hypothyroidism (2) 600 renal cell carcinoma Surgery
Diarrhea (1) 800 hepatocellular carcinoma TACE, RFA
aMolecular-targeted therapy.
Abbreviations: TACE: transarterial chemoembolization; RFA: radiofrequency ablation.
Table 3 Details of supportive care or suggestions by the
medical supportive team
Category For patients For physicians
Hand-foot skin reaction 11 3
Interaction of drugs 4 0
Diarrhea 3 8
Hypertension 2 6
Other adverse drug reactions 6 12
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one outpatient refused to continue the sorafenib treatment
due to anorexia. The dose of sorafenib was decreased to
600 mg/day in a patient with hypothyroidism; however,
inn this case, sorafenib treatment was discontinued
without endocrine therapy such as thyroid gland auxiliary
therapy.
Activities of the medical supportive team for outpatients
Mean daily doses of sorafenib were lower in the inter-
vention group (486.5 ± 198.6 mg (median, 480.8 mg)) than
in the non-intervention group (581.8 ± 196.0 mg (median,
600 mg)) (P = 0.048). Furthermore, no significant differences
were observed in the mean initial doses of sorafenib between
the intervention group (709.7 ± 170.0 mg (median, 800 mg))
and the non-intervention group (702.6 ± 170.9 mg (median,
800 mg)). The medical supportive team spent an average of
37.1 ± 11.1 min per outpatient (median, 40 min), and the
total number of interventions was 146. A total of 61 inter-
ventions in the intervention group concerned suggestions
on medication to physicians and outpatients. Table 3 shows
the medical supportive team’s suggestions to physicians
and patients. The incidences of adverse drug reactions,
apart from those of grades 3–4, such as hand-foot skin
reaction, diarrhea, anorexia, hair loss, thrombocytopenia,
hoarseness, increased serum amylase, fatigue, and stoma-
titis, were higher in the intervention group than in the
non-intervention group (Table 4).
Discussion
In this study, the duration of treatment with sorafenib was
significantly increased due to interventions by the medical
supportive team for outpatients. The supportive team per-
formed clinical management that included checking the
adherence of patients to the use of moisturizing lotion for
hand-foot skin reactions. If outpatients had not properly
followed the instructions, we participated in pharmaceut-
ical care including patient education for swabbing the
ointment to avoid serious hand-foot skin reactions. Previ-
ous prospective or randomized trials had not determined
the best management of hand-foot skin reactions causedby treatment with sorafenib. However, early use of a
moisturizer was recommended to avoid hand-foot skin
reaction symptoms [9,13,14]. Furthermore, the incidences
of sorafenib-induced adverse drug reactions and hand-foot
skin reactions were shown to be higher in Japanese pa-
tients than in European ones [10]. The medical supportive
team performed clinical management that included four
main activities; 1) checking adverse drug reactions before
the physician’s consultation; 2) medication use evaluations
based on laboratory data; 3) checking for adherence to
sorafenib; and 4) providing drug information and life-
style care points to patients in our hospital. It is hoped
that the clinical activities of the medical supportive team
will enhance the quality of sorafenib medication. In the
present study, the discontinuation of sorafenib treatment
by outpatients did not occur due to frequent communica-
tion with the medical supportive team. For this reason, the
early stages of hand-foot skin reactions were detected by
the medical supportive team.
On the other hand, information on the appropriate use
of sorafenib suggests that treatment with it should be
interrupted until recovery to Grades 0–1 when Grade 3
hand-foot skin reactions occur. Furthermore, if patients
recover from this symptom, decreases of 400 mg in the
dose (daily or alternate-day treatment) should be imple-
mented when administration is resumed. The incidence of
Table 4 Incidence of adverse drug reactions
Adverse drug reactions Intervention group (n = 31) n (%) Non-intervention group (n = 39) n (%) P-value (Any)
Grade Any 3 ~ 4 Any 3 ~ 4
Hand-foot skin reactiona 23(74.2) 2(6.5) 19(48.7) 3(7.7) 0.049*
Diarrhea 21(67.7) 2(6.5) 5(12.8) 1(2.6) < 0.001**
Hypertension 16(51.6) 6(19.4) 15(38.5) 5(12.5) 0.336
Anorexia 15(48.4) 1(3.2) 6(15.4) - 0.002**
Hair loss 13(41.9) - 5(12.8) - 0.012*
Thrombocytopenia 11(35.5) 2(6.5) 4(10.3) 3(7.7) 0.018*
AST increased 11(35.5) 5(16.1) 6(15.4) 3(7.7) 0.091
Hoarseness 10(32.3) - 4(10.3) - 0.034*
ALT increased 9(29.0) - 6(15.4) 3(7.7) 0.242
Serum amylase increased 9(29.0) 6(19.4) 3(7.7) 1(2.6) 0.026*
Fatigue 7(22.6) - 1(2.6) - 0.018*
Stomatitis 6(19.4) - 1(2.6) - 0.039*
Hypothyroidism 5(16.1) - 3(7.7) - 0.452
Blood bilirubin increased 5(16.1) 1(3.2) 3(7.7) 1(2.6) 0.452
Rash maculo-papular 4(12.9) - 4(10.3) - 1.000
aPalmar-plantar erythrodysesthesia syndrome (NCI-CTCAE).
*P < 0.05.
**P < 0.01.
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group than in the non-intervention group. These results
together with the significantly low mean doses of sorafenib
and higher incidence of adverse drug reactions in the
intervention group suggest that the supportive team
had a detailed interview with patients regarding adverse
effects. Thus, interventions by the supportive team helped
primary care physicians to reduce the sorafenib dose and
appropriately prescribe supportive therapies. However, this
study has the following limitations. Patients with advanced
renal cell carcinoma were included in the non-intervention
group. In patients with renal cell carcinoma, since
molecular-targeted drugs other than sorafenib can be
selected, there is a possibility that sorafenib treatment
was readily discontinued. Some studies have suggested
an association between prolongation of the sorafenib
treatment period and clinical effects [15-17]. In addition,
although there has been no evidence on the appropriate
sorafenib dose in the Japanese, some studies have shown
effects of sorafenib even at a small dose [18-20]. These
findings suggest that measures against adverse effects
taken by a supportive team prevent premature discon-
tinuation of sorafenib treatment.
Conclusions
In conclusion, the medical supportive team-implemented
management of pharmaceutical care contributed to con-
tinuation of the use of sorafenib in outpatients. Further-
more, the activities of the medical supportive team areimportant not only for outpatients treated with sorafenib,
but also for those with other molecular-targeted drugs
used in other hospitals.
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